Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reza Movahed

Dentist, Oral and Maxillofacial Surgery Chesterfield, MO Doctor of Dentistry

NPI 1790923365 CMS profile 585159

1585 Woodlake Dr Ste 208, Chesterfield, MO 63017

Open in the dashboard

General payments

$72,436

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Reza Movahed of Chesterfield, MO is reported in the CMS Open Payments database as having received $72,436 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,980 30
2024 General $1,230 12
2023 General $32,683 16
2022 General $840 15
2021 General $2,012 18
2020 General $2,659 22
2019 General $3,031 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reza Movahed
  • Dentist, Oral and Maxillofacial Surgery median
  • Middle half of Dentist, Oral and Maxillofacial Surgery
  • National median

In program year 2025, general payments to Reza Movahed were reported at $29,980. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.

Show as a table
Year Reza Movahed Dentist, Oral and Maxillofacial Surgery median Middle half National median
2019 $3,031 $142 $50–$420 $163
2020 $2,659 $96 $36–$277 $114
2021 $2,012 $138 $45–$419 $132
2022 $840 $144 $48–$367 $149
2023 $32,683 $153 $55–$399 $160
2024 $1,230 $152 $50–$400 $164
2025 $29,980 $150 $56–$423 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. KLS-Martin L.P. $30,217 34 payments
  2. Medical Device Business Services, Inc. $20,714 12 payments
  3. Straumann USA LLC $17,553 49 payments
  4. Synthes USA Products LLC $1,172 8 payments
  5. Salvin Dental Specialties, Inc. $622 5 payments
  6. Stryker Corporation $593 5 payments
  7. DePuy Synthes Sales Inc. $526 8 payments
  8. Nobel Biocare USA $322 7 payments
  9. Ultradent Products Inc $279 1 payment
  10. Zimmer Biomet Holdings, Inc. $149 2 payments
  11. Other $289 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $26,250 8 payments
  2. Consulting Fee $18,450 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,500 3 payments
  4. Travel and Lodging $5,673 17 payments
  5. Food and Beverage $4,702 70 payments
  6. Gift $3,287 27 payments
  7. Education $575 9 payments
Products named General payments · program years 2019–2025
  1. NA $18,400 3 payments
  2. IPS,IMPLANT, MANDIBLE, 00065,TI-6AL-4V,QTY:001 EA $14,515 1 payment
  3. IPS,CUTTING GUIDE, W/PLANNING, RECON,QTY:001 EA $5,098 1 payment
  4. MATRIXCOMBO $2,190 7 payments
  5. IPS,MARKING GUIDE, ORTHOG/MAX, 00196,QTY:001 EA $2,004 1 payment
  6. IPS,SPLINT, ORTHOG, DOUBLE JAW, SET,QTY:001 EA $1,749 1 payment
  7. IPS,SUPPLEMENTAL MODEL, HALF, 00006,QTY:001 EA $1,150 1 payment
  8. IPS,MARKING GUIDE, ORTHOG/MAND, 00197,QTY:001 EA $1,002 1 payment
  9. IPS,SPLINT, ORTHOG, SUPPLEMENTAL,QTY:001 EA $650 1 payment
  10. TRUMATCH $470 8 payments
  11. Other $2,838 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

706

Median for Oral Surgery (Dentist only): 288

Drug cost

$3,621

Median for Oral Surgery (Dentist only): $1,122

Branded share of claims

42.6%

Median for Oral Surgery (Dentist only): 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 144 $1,192
Chlorhexidine Gluconate Generic 180 $630
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 100 $562
Ondansetron Hcl Generic 124 $445
Methylprednisolone Generic 45 $256
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $182
Ondansetron Odt Ondansetron Brand 14 $125
Clindamycin Hcl Generic 11 $106
Ibuprofen Generic 28 $68
Azithromycin Generic 17 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,440 Part D prescribers listed as Oral Surgery (Dentist only); they describe a distribution and say nothing about conduct.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record